Cross-Sector entity
Of the tracked stories, 3 of 6 also mention Alignment Healthcare, the most common co-covered peer. Across a 116-day span, the pace is roughly 0.4 stories per week. The busiest single day carried 2. The clearest coverage concentration is market-trends: 3 of 6 stories, with the rest divided among 1 other category.
6 verified stories tracked
Last mentioned: Jun 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 6 also mention Alignment Healthcare, the most common co-covered peer. Across a 116-day span, the pace is roughly 0.4 stories per week. The busiest single day carried 2. The clearest coverage concentration is market-trends: 3 of 6 stories, with the rest divided among 1 other category. Negative sentiment appears in 0% of the tracked stories. This profile follows 6 Cross-Sector stories mentioning Baird across the period from February 25, 2026 to June 20, 2026. Each carries 3 original sources on average.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Baird. Shared-story counts are live from our verified record — not editorial picks.
Merger Reports
Reports surface regarding potential merger discussions between Estée Lauder and Puig.
Insider Selling
President and another insider report share sales in regulatory filings.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Agency Shift
Estée Lauder appoints WPP as its global media agency partner.
M&A Strategy
Estée Lauder CEO expresses openness to strategic acquisitions to aid turnaround.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
CarMax stock rebounded sharply after analysts issued bullish revisions; Stephens upgraded to buy with a $66 target, Baird raised to $55, and even J.P. Morgan lifted its target slightly.
CarMax’s Q1 results beat estimates, but investors sold off initially. Then Stephens upgraded the stock to buy with a $66 target, highlighting its used-car dominance, and shares rebounded sharply.
Source: The Motley Fool · Eric Volkman (us)
Estée Lauder is reportedly in strategic merger discussions with Spanish beauty giant Puig as part of an aggressive turnaround plan. Meanwhile, Zions Bancorporation and Boreal Carbon Corp are drawing significant investor attention following analyst upgrades and shifting sentiment in environmental markets.
Source: seekingalpha.com · Seeking Alpha
Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Source: tickerreport.com · themarketsdaily.com
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.
